Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Desai, Rita (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S386000
Reexamination Certificate
active
06878732
ABSTRACT:
A NK1antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough:
REFERENCES:
patent: 4629727 (1986-12-01), Kozlik et al.
patent: 5620989 (1997-04-01), Harrison et al.
patent: 6455571 (2002-09-01), Maring et al.
Kozlik et al, 1984, CAS:101:210713.*
Holan, et al. “Synthesis and insecticidal properties of ether analogs of DDT-pyrethroids” Chemical Abstracts Service, Columbus, Ohio, US, retrieved from STN Database accession no. 106:214159 (1986).
Heal, “Sibutramine: A novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine”International Journal of Obesity22, Suppl. No. 1:S18-S28 (1998).
PCT International Search Report dated Jul. 2, 2003 for corresponding PCT Application No. PCT/US03/07633.
Reichard Gregory A.
Shih Neng-Yang
Wrobleski Michelle Laci
Xiao Dong
Blinka Thomas A.
Desai Rita
Schering Corporation
Shiao Robert
LandOfFree
NK1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NK1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NK1 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3427077